Lat­est on re­ver­ber­a­tions of abor­tion pill rul­ing; Biotech ven­ture fund­ing dips; No­vo Nordisk dives in­to di­a­betes cell ther­a­py; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER